Literature DB >> 21653540

Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Nicolaas I Bohnen1, Martijn L T M Müller, Natalia Zarzhevsky, Robert A Koeppe, Christopher W Bogan, Michael R Kilbourn, Kirk A Frey, Roger L Albin.   

Abstract

Leucoaraiosis is associated with motor symptoms in otherwise normal older adults. Comorbid leucoaraiosis is predicted to contribute also to motor features in Parkinson's disease but previous studies of white matter changes in Parkinson's disease show variable results. No prior studies have compared directly the effects of both leucoaraiosis and the degree of nigrostriatal dopaminergic denervation on motor features. We investigated the effect of leucoaraiosis severity on motor impairment independent of the degree of nigrostriatal dopaminergic denervation in Parkinson's disease. Seventy-three subjects with Parkinson's disease (Hoehn and Yahr stages 1-3) underwent brain magnetic resonance and [(11)C]dihydrotetrabenazine vesicular monoamine transporter type 2 positron emission tomography imaging. Automated assessment of supratentorial fluid-attenuated inversion recovery magnetic resonance hyperintense white matter voxels was performed using cerebellar white matter as the intensity reference. White matter signal hyperintensity burden was log-transformed and normalized for brain volume. Unified Parkinson's Disease Rating Scale total and subscore ratings were assessed to determine motor impairment. Subjects receiving dopaminergic medications were examined in the clinically defined 'OFF' state. Multivariate regression analysis with measures of white matter signal hyperintensity burden and nigrostriatal denervation as independent variables demonstrated a significant overall model for total motor Unified Parkinson's Disease Rating Scale scores (F  = 11.4, P < 0.0001) with significant regression effects for both white matter signal hyperintensity burden (t  = 2.0, β = 0.22, P = 0.045) and striatal monoaminergic binding (t = -3.5, β = -0.38, P = 0.0008). Axial motor impairment demonstrated a robust association with white matter signal hyperintensity burden (t  = 4.0, β = 0.43, P  =0.0001) compared with striatal monoaminergic binding (t = -2.1, β = 0.22, P = 0.043). White matter signal hyperintensity burden regression effects for bradykinesia had borderline significance. No significant white matter signal hyperintensity burden effects were found for rigidity or tremor subscores. White matter signal hyperintensity burden was significantly higher in the subgroup with postural instability and gait difficulties compared with the tremor-predominant subgroup despite no significant differences in age or duration of disease. These findings indicate that increased white matter signal hyperintensity burden is associated with worse motor performance independent of the degree of nigrostriatal dopaminergic denervation in Parkinson's disease. Comorbid white matter disease is a greater determinant of axial motor impairment than nigrostriatal dopaminergic denervation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653540      PMCID: PMC3155702          DOI: 10.1093/brain/awr139

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  54 in total

1.  Where vascular meets neurodegenerative disease.

Authors:  Julie A Schneider; David A Bennett
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

2.  Association of gait and balance disorders with age-related white matter changes: the LADIS study.

Authors:  H Baezner; C Blahak; A Poggesi; L Pantoni; D Inzitari; H Chabriat; T Erkinjuntti; F Fazekas; J M Ferro; P Langhorne; J O'Brien; P Scheltens; M C Visser; L O Wahlund; G Waldemar; A Wallin; M G Hennerici
Journal:  Neurology       Date:  2008-03-18       Impact factor: 9.910

3.  Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study.

Authors:  W T Longstreth; T A Manolio; A Arnold; G L Burke; N Bryan; C A Jungreis; P L Enright; D O'Leary; L Fried
Journal:  Stroke       Date:  1996-08       Impact factor: 7.914

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Loss of white matter integrity is associated with gait disorders in cerebral small vessel disease.

Authors:  Karlijn F de Laat; Anil M Tuladhar; Anouk G W van Norden; David G Norris; Marcel P Zwiers; Frank-Erik de Leeuw
Journal:  Brain       Date:  2010-12-14       Impact factor: 13.501

7.  Axial signs and magnetic resonance imaging correlates in Parkinson's disease.

Authors:  Hernish J Acharya; Thomas P Bouchard; Derek J Emery; Richard M Camicioli
Journal:  Can J Neurol Sci       Date:  2007-02       Impact factor: 2.104

8.  Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

Authors:  F J Vingerhoets; M Schulzer; D B Calne; B J Snow
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

9.  Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Hiroto Kuwabara; Gregory M Constantine; Chester A Mathis; Robert Y Moore
Journal:  Neurosci Lett       Date:  2007-08-06       Impact factor: 3.046

10.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12
View more
  37 in total

Review 1.  The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.

Authors:  Branislav Veselý; Angelo Antonini; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2015-10-19       Impact factor: 3.575

2.  Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

Review 3.  An updated diagnostic approach to subtype definition of vascular parkinsonism - Recommendations from an expert working group.

Authors:  Ivan Rektor; Nicolaas I Bohnen; Amos D Korczyn; Viktoria Gryb; Hrishikesh Kumar; Milica G Kramberger; Frank-Erik de Leeuw; Zvezdan Pirtošek; Irena Rektorová; Ilana Schlesinger; Jaroslaw Slawek; Peter Valkovič; Branislav Veselý
Journal:  Parkinsonism Relat Disord       Date:  2017-12-29       Impact factor: 4.891

4.  Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations.

Authors:  Christina Sundal; Shinsuke Fujioka; Jay A Van Gerpen; Christian Wider; Alexandra M Nicholson; Matt Baker; Elizabeth A Shuster; Jan Aasly; Salvatore Spina; Bernardino Ghetti; Sigrun Roeber; James Garbern; Alex Tselis; Russell H Swerdlow; Bradley B Miller; Anne Borjesson-Hanson; Ryan J Uitti; Owen A Ross; A Jon Stoessl; Rosa Rademakers; Keith A Josephs; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2013-06-17       Impact factor: 4.891

5.  Motor and non-motor symptoms in old-age onset Parkinson's disease patients.

Authors:  Marcelo D Mendonça; Tania Lampreia; Rita Miguel; André Caetano; Raquel Barbosa; Paulo Bugalho
Journal:  J Neural Transm (Vienna)       Date:  2017-03-17       Impact factor: 3.575

6.  Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Stephanie Studenski; Kirk A Frey; Nicolaas I Bohnen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-05-26       Impact factor: 6.053

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

8.  Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes.

Authors:  Yuan Shen; Zhi-Feng Dong; Ping-Lei Pan; Gang Xu; Jun-Ying Huang; Chun-Feng Liu
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307

9.  Subtype definition of vascular parkinsonism.

Authors:  Ivan Rektor; Nicolaas I Bohnen; Amos D Korczyn
Journal:  Parkinsonism Relat Disord       Date:  2018-03-09       Impact factor: 4.891

Review 10.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.